Rankings
▼
Calendar
AMRX Q4 2025 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMRX
Amneal Pharmaceuticals, Inc.
$4B
Q4 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$814M
+11.5% YoY
Gross Profit
$297M
36.5% margin
Operating Income
$115M
14.1% margin
Net Income
$35M
4.3% margin
EPS (Diluted)
$0.11
QoQ Revenue Growth
+3.8%
Cash Flow
Operating Cash Flow
$130M
Free Cash Flow
$87M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$3.7B
Total Liabilities
$3.7B
Stockholders' Equity
-$71M
Cash & Equivalents
$311M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$814M
$731M
+11.5%
Gross Profit
$297M
$263M
+13.1%
Operating Income
$115M
$76M
+51.1%
Net Income
$35M
-$31M
+212.9%
Revenue Segments
Specialty Segment
$420M
100%
Geographic Segments
Specialty Segment
$275M
100%
← FY 2025
All Quarters